Foghorn Therapeutics presents favorable data for BRM selective inhibitor, FHD-909, in BRG1 mutated cancers, with IND filing planned Q2 2024.
Foghorn Therapeutics shares preclinical data for its first-in-class BRM selective inhibitor, FHD-909, showing favorable tolerability and dose-dependent single-agent activity in BRG1 mutated cancers. The company also reports robust preclinical monotherapy anti-tumor activity for selective CBP and selective EP300 degrader programs. An IND filing for FHD-909 is on track for Q2 2024, validating Foghorn's drug discovery engine.
April 09, 2024
5 Articles